Generic Name

Bremelanotide Acetate

---

Classification

FDA Approved Indications

• Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women

Mechanism of Action

Bremelanotide is a melanocortin receptor agonist that modulates neural pathways involved in sexual desire, leading to increased libido in women with HSDD.

Dosage and Administration

Adult: 30 mg injected subcutaneously once, at least 45 minutes before sexual activity, no more than once in 24 hours.

Pediatric: Not approved for pediatric use.

Geriatric: Limited data; use with caution, starting at lower doses.

Renal Impairment: No specific adjustments recommended; monitor for efficacy and tolerability.

Hepatic Impairment: Use with caution; no specific dose adjustments established.

Pharmacokinetics

Absorption: Rapid absorption following subcutaneous injection.

Distribution: Widely distributed, crosses the blood-brain barrier.

Metabolism: Primarily metabolized by proteolytic enzymes.

Excretion: Excreted mainly in urine; minimal unchanged drug recovered.

Half Life: Approximately 2 hours.

Contraindications

• History of hypersensitivity to Bremelanotide or any components.
• Use with caution in patients prone to cardiovascular disease or with uncontrolled hypertension.

Precautions

• Monitor blood pressure; avoid in patients with known hormone-sensitive cancers or during pregnancy and breastfeeding.
• Not recommended for use with other potent vasoconstrictive agents or medications affecting blood pressure.

Adverse Reactions - Common

• Nausea (Very common)
• Vomiting (Common)
• Injection site reactions (pain, redness, irritation) (Common)
• Flushing (Common)

Adverse Reactions - Serious

• Transient increases in blood pressure (Uncommon)
• Anaphylaxis (Rare)
• Darkening of the skin in treated areas (Rare)

Drug-Drug Interactions

• Other vasoconstrictors, agents affecting blood pressure, or serotonergic drugs.

Drug-Food Interactions

N/A

Drug-Herb Interactions

N/A

Nursing Implications

Patient/Family Teaching

• Instruct on proper use of the autoinjector.
• Report any adverse reactions, especially rapid changes in blood pressure or allergic reactions.
• Do not use more than once in 24 hours.

Special Considerations

Black Box Warnings:

• Potential for severe hypoperfusion and ischemia in some patients, especially those with cardiovascular risks.

Genetic Factors: No specific genetic factors impacting use.

Lab Test Interference: No significant interference reported.

Overdose Management

Signs/Symptoms: Excessive vasoconstriction, hypertensive crisis, or allergic reactions.

Treatment: Discontinue drug; provide supportive care, antihypertensive treatment if necessary; seek emergency care.

Storage and Handling

Storage: Store at controlled room temperature, away from moisture and light.

Stability: Stable until the expiration date on the packaging.